Oragenics (NYSE:OGEN) Earns Sell Rating From Analysts at StockNews.com
Oragenics (NYSE:OGEN) Earns Sell Rating From Analysts at StockNews.com
StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the stock.
Oragenics Stock Performance
Shares of NYSE OGEN opened at $3.31 on Monday. The stock has a market cap of $6.49 million, a PE ratio of -0.43 and a beta of 0.37. Oragenics has a 12-month low of $2.61 and a 12-month high of $24.00.
Get Oragenics alerts:Oragenics Company Profile
(Get Rating)
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Further Reading
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the stock.
StockNews.com 開始報道的股票 Oragenics（紐約證券交易所代碼：OGEN — 獲取評級） 在週一上午發佈的一份報告中。該公司對該股發佈了賣出評級。
Oragenics Stock Performance
Oragenics 股票表現
Shares of NYSE OGEN opened at $3.31 on Monday. The stock has a market cap of $6.49 million, a PE ratio of -0.43 and a beta of 0.37. Oragenics has a 12-month low of $2.61 and a 12-month high of $24.00.
紐約證券交易所OGEN的股票週一開盤價爲3.31美元。該股票的市值爲649萬美元，市盈率爲-0.43，beta值爲0.37。Oragenics的12個月低點爲2.61美元，爲12個月高點24.00美元。
Oragenics Company Profile
Oragenics 公司簡介
(Get Rating)
（獲取評級）
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Oragenics Inc是一家生物技術公司，專注於開發和許可用於改善人類健康的創新產品和技術。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免費獲取 StockNews.com 關於 Oragenics (OGEN) 的研究報告
- ASML報告了大規模增長，管理層指出2023年表現疲軟
- 分析師 Boost 會讓洛克希德·馬丁公司的股價上漲、上漲和下跌嗎？
- Mullen Automotive：是玫瑰花的嗎？
- 多元化的雅培實驗室可能會逆轉並走高
- 催化劑接近時Okta的逆轉正在進行中
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Oragenics及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧